Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Financing Activities (2016 - 2025)

Cytosorbents filings provide 15 years of Cash from Financing Activities readings, the most recent being $2.5 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 1383.83% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.3 million, a 0.24% change, with the full-year FY2025 number at $9.3 million, changed 0.24% from a year prior.
  • Cash from Financing Activities hit $2.5 million in Q4 2025 for Cytosorbents, up from -$1134.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $12.2 million in Q4 2023 to a low of -$571762.0 in Q1 2024.
  • Median Cash from Financing Activities over the past 5 years was $589718.0 (2021), compared with a mean of $2.3 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 6278.64% in 2022 and later crashed 183.56% in 2024.
  • Cytosorbents' Cash from Financing Activities stood at -$80924.0 in 2021, then skyrocketed by 6278.64% to $5.0 million in 2022, then surged by 144.21% to $12.2 million in 2023, then crashed by 98.63% to $167000.0 in 2024, then soared by 1383.83% to $2.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were $2.5 million (Q4 2025), -$1134.0 (Q2 2025), and $6.8 million (Q1 2025) per Business Quant data.